Biocentis

Biocentis is a life-science company that describes itself as "shaping the future of insect control." A spin-out from Imperial College London, the company builds on two decades of research by its scientific founders and combines genome engineering, artificial intelligence, and a proprietary technology platform to develop insect control solutions that it positions as highly effective, environmentally friendly, and sustainable. The company operates with teams in both the United Kingdom and Italy, and its corporate presence is associated with Milan, Italy. The company frames its mission around three interconnected global problems. First, agricultural pests threaten food security: Biocentis cites FAO figures that 25% of crops are destroyed by insect pests and that the world will need 60% more food by 2050. Second, insect vector-borne diseases remain an unsolved global emergency, with dengue spreading rapidly and imposing an estimated $40 billion yearly economic burden. Third, invasive species threaten ecosystems and biodiversity, causing more than $70 billion in damages every year. Biocentis argues that continued reliance on chemical insecticides is unsustainable because of pesticide pollution and growing pest resistance, and it positions its genetic control technology as the answer. Biocentis is led by a founding team with backgrounds in entrepreneurship, consulting, and molecular biology. Co-founder and Director Teodoro D'Ambrosio is a serial entrepreneur who previously co-founded Prima Assicurazioni, Bravoavia (acquired by Bravofly), Hotelscan (acquired by JetCost), Emaze, and Neulabs; those ventures collectively have a combined value exceeding €3 billion, and he has secured more than €500 million in funding from investors including Goldman Sachs, Blackstone, and Carlyle. Co-founder and CEO Giorgio Rocca was previously a strategy consultant at Boston Consulting Group advising healthcare and life-sciences clients; he is trained as an engineer and leads the company's mission to redefine insect control through sustainable biotechnology. The company also highlights an award-winning molecular biologist among its scientific leadership. As a private, venture-backed company, Biocentis does not disclose a stock listing. Its public communications emphasize the scale of the problems it addresses and the ambition of its platform rather than commercial product sales, reflecting its stage as a research-driven biotechnology venture.

Biocentis is a spin-out from Imperial College London, a global powerhouse of science, innovation, and discovery. The company builds on two decades of ground-breaking research by its scientific founders. It operates with teams in the UK and Italy, and its corporate presence is associated with Milan, Italy. The company was founded by a team combining entrepreneurial and scientific expertise. Teodoro D'Ambrosio, a serial entrepreneur with over 20 years of experience, co-founded Prima Assicurazioni, Bravoavia (acquired by Bravofly), Hotelscan (acquired by JetCost), Emaze, and Neulabs before founding Biocentis; those ventures collectively have a combined value exceeding €3 billion, and he has secured more than €500 million in funding from top institutional investors such as Goldman Sachs, Blackstone, and Carlyle. Giorgio Rocca, who worked as a strategy consultant at the Boston Consulting Group advising leading companies in healthcare and life sciences, co-founded Biocentis and serves as Chief Executive Officer. He holds a BSc and MSc in Mechanical Engineering from the University of Genova and MBAs from Collège des Ingénieurs and INSEAD. The company also brings together experts who have built companies worth billions, pioneered CRISPR technologies, and delivered some of the world's most advanced insect control solutions. Biocentis positions its work against three global challenges. Agricultural pests pose a huge threat to food security worldwide, with 25% of crops destroyed by insect pests and a need for 60% more food by 2050. Insect vector-borne diseases are an unsolved global emergency, with 5.5 billion people at risk, 700,000 annual deaths, 400 million annual infections, and dengue spreading at an alarming pace with an estimated $40 billion yearly economic burden. Invasive species threaten ecosystems and biodiversity, causing more than $70 billion in damages every year. The company argues that continued reliance on chemical insecticides is unsustainable, citing more than 2,700 million tonnes of pesticides used annually, more than 60% of global agricultural land at risk of pesticide pollution, and more than 300 insecticides hampered by resistance from pests. Biocentis develops next-generation genetic control technology that harnesses biology to provide highly effective and sustainable insect control. Its platform combines genome engineering, artificial intelligence, and a unique technological platform. The company's mission is to revolutionize how the world controls harmful insects, protecting health, agriculture, and biodiversity.

• Biocentis is founded as a spin-out from Imperial College London, building on two decades of research by its scientific founders.

• Teodoro D'Ambrosio and Giorgio Rocca co-found Biocentis.

A life-science company re-shaping the future of insect control with a unique technology platform that combines environmental sustainability and unprecedented effectiveness.

• Next-generation genetic control technology

  Harnesses biology to provide highly effective and sustainable insect control.

• Genome engineering platform

  Leverages the latest advancements in genome engineering.

• AI-driven insect control solutions

  Combines artificial intelligence with a unique technological platform.

1. 1Biocentis - Shaping the future of insect controlbiocentis.com
2. 2Biocentis - Companybiocentis.com
3. 3Biocentis (Italy) - Wikidatawikidata.org